NCT06464679View on ClinicalTrials.gov

An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2026

Conditions
Autoimmune Diseases
Interventions
BIOLOGICAL

anti-CD19 CAR NK cells

Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of CD19 CAR NK cells will infused using the dose-escalation strategy.

Trial Locations (1)

Unknown

RECRUITING

Changhai Hospital, Shanghai

All Listed Sponsors
collaborator

Rui Therapeutics

UNKNOWN

lead

Changhai Hospital

OTHER